Skip to main content

Articles

Original Research, Practice Management

Reducing the Price of Total Hip Arthroplasty Implant Costs Through Reference Pricing: An Economic Evaluation

Christopher J. Fang, MD; Jonathan M. Shaker, MS; Daniel M. Ward, MD; Carl T. Talmo, MD; Andrew Jawa, MD; David A. Mattingly, MD; Eric L. Smith, MD

Original Research, Practice Management

Cost-Effectiveness of de novo Simvastatin as Adjunctive Therapy in Patients Critically Ill with Sepsis

Sara Mostafa Eladawy, MSc, PhD; Mohamed Abd Alsalam Elgendy, MD; Mamdouh Ahmed Zaki, MD; Naglaa Samir Bazan, MSc, PhD

FDA Oncology Update, FDA Approvals

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

FDA Oncology Update, FDA Approvals

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

FDA Oncology Update, FDA Approvals

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Oncology Update, FDA Approvals

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

FDA Oncology Update, FDA Approvals

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

Adjunctive Lipid-Lowering Strategies for Patients Needing Additional LDL-C Lowering

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

Page 12 of 244
Results 111 - 120 of 2440